Wockhardt Aims For $12m Annual Savings Through US Restructuring
Plus Serum Vaccines Operation And Diabetes Biosimilars Could Bring Firm Back To Profitability
Executive Summary
Wockhardt expects to save up to $12m through restructuring its US business, eyeing up a potential return to profitability by 2025.
You may also be interested in...
After Consent Decree, Wockhardt May Sell US Site Amid Wider Revamp
Wockhardt’s US arm Morton Grove Pharmaceuticals, which is bound by a consent decree of permanent injunction, discontinues production to undertake an “orderly closure” and potential sale of its Illinois site. Indian parent firm taps contract manufacturers to service US market.
Wockhardt Expands UK Vaccines Unit With Serum Institute Deal
India’s Wockhardt has announced a fresh collaboration with the Serum Institute of India that will see the firm create a new sterile fill-and-finish facility in the UK, as part of plans to deliver an additional 150 million vaccine doses.
Glucagon And Epinephrine Continue To Drive Growth At Amphastar
Amphastar has delivered another successful quarter, bolstered by sales of glucagon and epinephrine, as it prepares to roll out a number of commercially attractive products and complete a significant branded product acquisition.